Research and Markets: PharmaLeaders: Mid-Cap Biotechnology Benchmark Report 2015 - Sales Forecasts and Product Valuations of Innovative Biotechs

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/wwnrhh/pharmaleaders) has announced the addition of the "PharmaLeaders: Mid-Cap Biotechnology Benchmark Report - Sales Forecasts and Product Valuations of Innovative Biotechs" report to their offering.

"PharmaLeaders: Mid-Cap Biotechnology Benchmark Report - Sales Forecasts and Product Valuations of Innovative Biotechs" applies our proprietary ranking methodology to compare the competitive positions of 35 mid-cap biotechnology companies on 14 financial metrics.

These companies are analyzed based on their financial performance, research and development (R&D) spending, capital structure, and firm utilization to illustrate the different strategies they are using to increase value for their shareholders and create a competitive advantage. Throughout the report, Our Industry Dynamics Team provides expert insight, expanding on each of the metrics discussed.

In addition to the financial metrics, this report provides an overview of the biotech sector growth rates, and discusses the regulatory approvals that occurred in 2014, along with our forecast sales outlook for each drug. We also examine how the patent cliff will impact the industry moving forward, along with deals and licensing activity, and the prospects for niche/orphan drugs. Lastly, we use our proprietary database tools to determine the Net Present Value (NPV) of both marketed and clinical pipeline assets and their future profits and cash flows.

Scope

- This report provides analysis of the key drivers and trends shaping the biotechnology sector; including drivers of financial growth and R&D spending, FDA approvals, generic erosion, corporate strategy, orphan drugs and asset value creation

- This report offers a deep dive into the synergies behind partnering and acquisition activity

- FDA expedited review - drugs approved by Fast Track, Breakthrough, Priority Review, and Accelerated approval pathways

- Six-year forecasts for key drugs approved in 2014; Net Present Value (NPV) for key drugs approved in 2014.

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Market Dynamics

3.1 Sector Fundamentals

3.2 FDA Approved 41 New Drugs in 2014

3.3 Orphan Drugs: No Longer a Rare Opportunity

3.4 FDA Approved 27 New Drugs in 2013

3.5 Patent Cliff to Erode $65 Billion in Sales by 2019

4 Collaboration and Acquisition Strategies

4.1 Deals Landscape

4.2 M&A Analysis

4.3 Licensing and Partnership Deals

5 Financial Management

5.1 Revenue

5.2 Year-to-Year Revenue Growth

5.3 Operating Income

5.4 Gross Profit Margin

5.5 Expense Performance Metrics

5.6 Liquidity and Valuation Metrics

6 Company Analysis

6.1 Acadia

6.2 Actelion

6.3 Alexion

6.4 BioMarin

6.5 Cubist

6.6 Incyte

6.7 Medivation

6.8 Pharmacyclics

6.9 Regeneron

6.10 Vertex

7 Future Outlook

8 Appendix

For more information visit http://www.researchandmarkets.com/research/wwnrhh/pharmaleaders

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals